MSC-Exos targeted integrin α1 (ITGA1) via the delivery of microRNA-192, leading to a significant reduction in angiogenesis-associated factors, including VEGFA and CD31, and mitigating Müller cell activation in diabetic retinopathy (Gu et al. 2021). Here, VEGFA is linked to diabetic retinopathy.